{"id":6036,"date":"2023-05-30T09:37:59","date_gmt":"2023-05-30T00:37:59","guid":{"rendered":"https:\/\/www.imedisync.com\/?p=6036"},"modified":"2023-05-30T11:20:34","modified_gmt":"2023-05-30T02:20:34","slug":"mila-and-imedisync-announce-partnership-to-advance-ai-for-mental-health","status":"publish","type":"post","link":"https:\/\/www.imedisync.com\/en\/mila-and-imedisync-announce-partnership-to-advance-ai-for-mental-health\/","title":{"rendered":"Mila and iMediSync announce partnership to advance AI for mental health"},"content":{"rendered":"
\n

\"\"<\/h1>\n

Mila and iMediSync announce partnership to advance AI for mental health<\/h1>\n
<\/div>\n<\/header>\n
\n

Mila \u2013 Quebec AI Institute,\u00a0the world\u2019s largest academic deep learning (DL) research center\u00a0announced today its partnership with\u00a0iMediSync<\/a>\u00a0whose mission is to innovate mental health by using a data-driven approach and artificial intelligence (AI) technologies. iMediSync is a Korean-based international digital mental healthcare company specializing in brainwave-centered diagnostics for early prediction and screening of various brain diseases and precision digital therapeutics using near-infrared light emitting diodes (NIR-LED). The collaboration between Mila and iMediSync signifies a significant leap forward in AI-driven mental healthcare, highlighting their commitment to solve the most serious social problems threatening our sustainability.<\/p>\n

\u201cWe are thrilled to partner with Mila, a world-leading institution in AI research. This collaboration allows us to harness the power of AI to develop cutting-edge solutions that will transform the diagnosis and treatment of brain dysfunctions,\u201d said Dr. Seung Wan Kang CEO of iMediSync. \u201cTogether, we will propel the field forward, leveraging our expertise and Mila\u2019s research prowess to make a tangible difference in patients\u2019 lives.\u201d<\/p>\n

The collaboration between Mila and iMediSync is to propel the intersection of AI and mental healthcare, fostering the creation of groundbreaking solutions for detecting and addressing brain dysfunctions. This partnership marks a significant stride forward for the field, paving the way for novel developments in diagnosis and treatment.<\/p>\n

\u201cAI already is an important technology in the mental health sector. With this partnership, we aim to think about new ways to put AI to use for people living with these health disorders. We are proud to welcome iMediSync in the Mila community. \u201d said St\u00e9phane L\u00e9tourneau, Executive Vice-President of Mila.<\/p>\n

About iMediSync\u00a0<\/b><\/p>\n

iMediSync is the innovative digital mental health platform company integrating FDA-cleared portable electroencephalogram (EEG) brain scanner with NIR-LED photobiomodulation and cloud-based quantitative electroencephalogram (QEEG) automatic analysis system targeting early detection and preventive care for dementia, Alzheimer\u2019s disease, mood problems, and other mental disorders, even at the preclinical stage. It\u2019s revolutionizing diagnostics and enhancing the accessibility to mental healthcare by digitizing conventional EEG with AI technology. iMediSync has successfully developed an AI\/ML algorithm for detecting mild cognitive impairment or Alzheimer\u2019s disease. iMediSync has partnered with over 25 hospitals and medical centers to improve mental health analysis and care especially after the effects of a pandemic.<\/p>\n

About Mila<\/b><\/p>\n

Founded by Professor Yoshua Bengio of the University of Montreal, Mila is an artificial intelligence research institute that brings together over 1,000 researchers specializing in machine learning. Based in Montreal, Mila\u2019s mission is to be a global hub for scientific advances that inspire innovation and development of AI for the benefit of all. Mila is a non-profit organization recognized worldwide for its significant contributions to the field of deep learning, particularly in language modeling, machine translation, object recognition, and generative models.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mila and iMediSync announce partnership to advance AI…<\/p>\n","protected":false},"author":1,"featured_media":6037,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[26],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/posts\/6036"}],"collection":[{"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/comments?post=6036"}],"version-history":[{"count":4,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/posts\/6036\/revisions"}],"predecessor-version":[{"id":6042,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/posts\/6036\/revisions\/6042"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/media\/6037"}],"wp:attachment":[{"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/media?parent=6036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/categories?post=6036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imedisync.com\/en\/wp-json\/wp\/v2\/tags?post=6036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}